Acerus Pharmaceuticals (OTCMKTS:ASPCF) and Hillstream Biopharma (NASDAQ:CNTN) Head to Head Review

Hillstream Biopharma (NASDAQ:CNTN) and Acerus Pharmaceuticals (OTCMKTS:ASPCF) are both small-cap manufacturing companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Institutional and Insider Ownership

1.2% of Hillstream Biopharma shares are owned by institutional investors. 3.3% of Hillstream Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Hillstream Biopharma and Acerus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-31.50%	-24.72%
Acerus Pharmaceuticals	-924.33%	N/A	-74.62%

Risk and Volatility

Hillstream Biopharma has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500. Comparatively, Acerus Pharmaceuticals has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Hillstream Biopharma and Acerus Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1	0	0	0	1.00
Acerus Pharmaceuticals	0	0	0	0	0.00

Earnings & Valuation

This table compares Hillstream Biopharma and Acerus Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92 million	($1.15)	-1.75
Acerus Pharmaceuticals	$2.12 million	0.80	-$33.82 million	($3.57)	-0.06

Acerus Pharmaceuticals has higher revenue and earnings than Hillstream Biopharma. Hillstream Biopharma is trading at a lower price-to-earnings ratio than Acerus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Hillstream Biopharma beats Acerus Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About Hillstream Biopharma

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.

About Acerus Pharmaceuticals

Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men’s health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.